Journal of the National Cancer Institute
Papers 10000
1 page of 1,000 pages (10k results)
#1Hoonsik Nam (SNU: Seoul National University)H-Index: 1
#2Sunmi Kang (SNU: Seoul National University)H-Index: 12
Last. Young Ju Suh (Inha University)H-Index: 15
view all 17 authors...
Background null Pancreatic cancer (PC) has a grim prognosis, and an early diagnostic biomarker has been highly desired. The molecular link between diabetes and PC has not been well-established. null Methods null Bioinformatics screening was performed for a serum PC marker. Experiments in cell lines (5 PC and 1 normal cell lines), mouse models, and human tissue staining (37 PC and 10 normal cases) were performed to test asprosin production from PC. Asprosin's diagnostic performance was tested wit...
#1Aaron P. Mitchell (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 9
#2Akriti A. Mishra (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 2
Last. Michael J. Morris (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 66
view all 6 authors...
Background null Bone modifying agent (BMA) therapy is recommended for metastatic castration-resistant prostate cancer (mCRPC) but not metastatic castration-sensitive prostate cancer (mCSPC). BMA treatment in mCSPC may therefore constitute overuse. null Methods null In this retrospective cohort study using linked Surveillance, Epidemiology, and End Results-Medicare data, we included patients diagnosed with stage IV prostate adenocarcinoma from 2007-2015, who were age ≥66 years at diagnosis and re...
#1Renée L Kokts-Porietis (AHS: Alberta Health Services)
#2Jessica McNeil (UNCG: University of North Carolina at Greensboro)H-Index: 17
Last. Christine M. Friedenreich (U of C: University of Calgary)H-Index: 89
view all 6 authors...
BACKGROUND Disease-free and overall survival associations with anthropometric measures of obesity and changes in these exposures remain unknown among endometrial cancer survivors. METHODS Endometrial cancer survivors diagnosed between 2002-2006 completed direct anthropometric measurements and self-reported lifetime weight history during in-person interviews approximately 4 months after diagnosis (peri-diagnosis) and approximately 3 years after diagnosis (follow-up). Participants were followed un...
#1Annette M. Molinaro (UCSF: University of California, San Francisco)H-Index: 55
#2John K. Wiencke (UCSF: University of California, San Francisco)H-Index: 94
Last. Terri Rice (UCSF: University of California, San Francisco)H-Index: 29
view all 18 authors...
Background null Tumor-based classification of human glioma portends patient prognosis; however, considerable unexplained survival variability remains. Host factors (eg, age) also strongly influence survival times, partly reflecting a compromised immune system. How blood epigenetic measures of immune characteristics and age augment molecular classifications in glioma survival has not been investigated. We assess the prognostic impact of immune-cell fractions and epigenetic age in archived blood a...
#1H. Amarens Geuzinge (EUR: Erasmus University Rotterdam)H-Index: 1
#2Marije F. Bakker (UU: Utrecht University)H-Index: 20
Last. Evelyn M. Monninkhof (UU: Utrecht University)H-Index: 54
view all 13 authors...
Background null Extremely dense breast tissue is associated with increased breast cancer risk and limited sensitivity of mammography. The DENSE trial showed that additional magnetic resonance imaging (MRI) screening in women with extremely dense breasts resulted in a substantial reduction in interval cancers. The cost-effectiveness of MRI screening for these women is unknown. null Methods null We used the MISCAN-breast microsimulation model to simulate several screening protocols containing mamm...
1 CitationsSource
#1Carlos A. García-Prieto (Barcelona Supercomputing Center)H-Index: 2
#2Lorea VillanuevaH-Index: 9
Last. Francesca Del Bufalo (Boston Children's Hospital)H-Index: 14
view all 26 authors...
BACKGROUND Chimeric antigen receptor (CAR) T-cells directed against CD19 (CART19) are effective in B-cell malignancies, but little is known about the molecular factors predicting clinical outcome of CART19 therapy. The increasingly recognized relevance of epigenetic changes in cancer immunology prompted us to determine the impact of the DNA methylation profiles of CART19 cells on the clinical course. METHODS We recruited 114 patients with B-cell malignancies, comprising 77 acute lymphoblastic le...
#1Vincenzo Formica (University of Rome Tor Vergata)H-Index: 19
#2Francesco Sera (UniFI: University of Florence)H-Index: 1
Last. Mario Roselli (University of Rome Tor Vergata)H-Index: 41
view all 7 authors...
BACKGROUND KRAS and BRAF mutations are well-established predictive and prognostic factors in metastatic colorectal cancer, however their impact in the adjuvant setting has not yet been established. METHODS We performed a meta-analysis of adjuvant phase III trials in patients with stage II and III colon cancer with available data on the impact of KRAS/BRAF mutations on both disease-free survival (DFS) and overall survival (OS). Trials were subgrouped based on whether adjustment for microsatellite...
#1Ichidai Tanaka (University of Texas MD Anderson Cancer Center)H-Index: 9
#2Delphine Audrey Dayde (University of Texas MD Anderson Cancer Center)H-Index: 2
Last. Rekha Jain (University of Texas MD Anderson Cancer Center)H-Index: 8
view all 43 authors...
BACKGROUND About 20% of lung adenocarcinoma (LUAD) is negative for the lineage-specific oncogene Thyroid transcription factor 1 (TTF-1) and exhibits worse clinical outcome with a low frequency of actionable genomic alterations. To identify molecular features associated with TTF-1-negative LUAD, we compared the transcriptomic and proteomic profiles of LUAD cell lines. SRGN, a chondroitin sulfate proteoglycan Serglycin, was identified as a markedly overexpressed gene in TTF-1-negative LUAD. We the...
#1Brittny C. Davis Lynn (NIH: National Institutes of Health)H-Index: 2
#2Pavel Chernyavskiy (UVA: University of Virginia)
Last. Philip S. Rosenberg (NIH: National Institutes of Health)H-Index: 81
view all 4 authors...
Background null Incidence of estrogen receptor (ER)-negative breast cancer, an aggressive subtype, is highest in United States (US) African American women and in southern residents but has decreased overall since 1992. We assessed whether ER-negative breast cancer is decreasing in all age groups and cancer registries among non-Hispanic White (NHW), non-Hispanic Black (NHB), and Hispanic White (HW) women. null Methods null We analyzed 17 Surveillance, Epidemiology, and End-Results Program registr...
Top fields of study